Fecal carriage of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae in Egyptian patients with community-onset gastrointestinal complaints: a hospital-based cross-sectional study

H.M. Abdallah, N. Alnaiemi, E.A. Reuland, B.B. Wientmans, A. Koek, A.M. Abdelwahab, A. Samy, K.W. Abdelsalam, and C.M.J.E. Vandenbroucke-Grauls

Abstract

Objectives: The aim of this study was to determine the prevalence of extended-spectrum β-lactamase (ESBL) and carbapenemase production among Enterobacteriaceae isolated from ambulatory patients with gastrointestinal complaints admitted to El-Ahrar General Hospital, Zagazig, Egypt in the period between January 2013 and May 2013.

Methods: One hundred and thirteen Enterobacteriaceae isolates were recovered from 100 consecutive Egyptian patients with community–onset gastrointestinal complaints. The fecal samples were plated directly on selective EbSA-ESBL Screening Agar and on MacConkey agar. Isolate identification was performed with matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Screening for ESBLs and carbapenemases production was done by both the automated VITEK®2 system with AST N198 and by disk diffusion method. Real-time PCR and sequencing were used to characterize the resistance genes. Phylotypes of the E. coli isolates were determined by a triplex PCR-based method.

(Continued on next page)
Results: Of 100 patients screened for fecal colonization with extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) and carbapenemase-producing Enterobacteriaceae (CPE), 68 were colonized with ESBL-E whereas five patients were positive for CPE. One hundred and thirteen Enterobacteriaceae isolates were recovered from 100 fecal samples, they belonged to E. coli (n = 72), Klebsiella pneumoniae (n = 23), Enterobacter cloacae (n = 3), Salmonella spp. (n = 1) and other Enterobacteriaceae isolates (n = 14). The blaCTX-M gene was detected in 89.04% (65/73) of the ESBL-producing Enterobacteriaceae, whereas blaSHV and blaTEM were detected in 30.14% (22/73) and 19.18% (14/73) respectively. Three out of 5 carbapenem-resistant isolates harbored New Delhi metallo-beta-lactamase (NDM) and 2 produced Verona integron-encoded metallo-beta-lactamase (VIM). Twenty-two (47.83%) of the ESBL positive isolates were multidrug resistant (MDR). Phylogenetic analysis showed that, of the 51 ESBL-EC isolates, 17 belonged to group B2, 13 to group D, 11 to group A and 10 to group B1.

Conclusions: Nearly two-thirds of the Enterobacteriaceae isolates recovered from feces of ambulatory patients with community-onset gastrointestinal complaints admitted to El-Ahrar General Hospital, Zagazig, Egypt were ESBL producers and one in every 20 patients included in our study was colonized by carbapenemase-producing Enterobacteriaceae. These high colonization rates are worrying, therefore prudent antimicrobial use should be adopted in Egyptian community settings.

Keywords: Carbapenemase-ESBL-Egypt-resistance-Enterobacteriaceae

Background
Infections due to extended-spectrum beta-lactamase--and carbapenemase-producing Enterobacteriaceae represent a major global health threat [1] since such bacteria are usually resistant to multiple antimicrobial agents and carbapenems are expensive and not always available, especially in less wealthy countries. Infections with these resistant strains are associated with treatment failure, high mortality, and increased healthcare costs [2–4].

ESBL-producing Enterobacteriaceae (ESBL-E) and carbapenemase-producing Enterobacteriaceae (CPE) are incriminated in both nosocomial and community-acquired infection [5, 6]. The fecal carriage rate of ESBL-E has mainly been investigated during nosocomial outbreaks, whilst few studies were conducted in community settings [5, 7]. High community carriage rates were reported in Thailand (69.3%) and China (50.5%) [8, 9]. Lower rates were demonstrated in most European countries (not more than 12%) and North America (less than 2%) [10–13]. In Egypt, data on the prevalence of ESBL-E in the community remain scarce. A study performed in Cairo (urban population) reported high fecal carriage rate (63.3%) of ESBL-E among healthy individuals [14]. To the best of our knowledge, no previous research has been carried out to determine the fecal carriage rate of CPE in the community. In this study, we aimed to assess the prevalence of ESBL-E and CPE among ambulatory patients with community--onset gastrointestinal complaints admitted to El-Ahrar General Hospital, Zagazig (semi-urban population, 65 km from Cairo), Egypt.

Methods
Bacterial isolates
This study was performed in the period between January 2013 and May 2013, at El-Ahrar General Hospital, Zagazig, Egypt, a 608-bed hospital affiliated to the Egyptian health ministry. Approximately 1.5 g of feces was collected aseptically from 100 consecutive patients admitted to the hospital with community–onset gastrointestinal complaints (one sample per patient). Fecal samples were obtained for routine diagnosis of the gastrointestinal complaints and in addition to routine testing for gastrointestinal pathogens. The patients had no past history of travel to the Indian subcontinent or to South-Eastern Asia, nor relatives that had recently traveled to those regions. Fecal samples were suspended in 5 mL of saline (0.9%) and 100 ul of each sample was plated directly on selective EbSA-ESBL Screening Agar [15] for the isolation of bacteria resistant to broad-spectrum cephalosporins and on MacConkey agar for the characterization of the dominant isolates. At least one and up to five colonies per agar plate were investigated. Bacteria were identified by the automated Vitek® MS system (BioMérieux, Marcy l’Étoile, France).

Phenotypic screening and confirmation of ESBL-E and CPE
Antibiotic susceptibility testing was performed by both the automated VITEK®2 system with AST card N198 (BioMérieux, Marcy l’Étoile, France) and by disk diffusion on Mueller-Hinton agar using ceftazidime (30 μg), cefotaxime (30 μg), meropenem (10 μg), and imipenem (10 μg) disks. The AST card antimicrobial agents panel were ampicillin, amoxicillin-clavulanic acid, piperacillin, piperacillin-tazobactam, cefturoxime, cefoxitin, cefepime, ceftazidime, cefotaxime, meropenem, imipenem, ciprofloxacin, norfloxacin, gentamicin, tobramycin, nitrofurantoin, and trimethoprim-sulfamethoxazole. The results of antibiotic susceptibility tests were interpreted according to the clinical breakpoints recommended by Clinical and...
Laboratory Standards Institute (CLSI) and the Dutch Society of Medical Microbiology [16, 17]. ESBL production was confirmed with the ESBL combination disks (Rosco, Taastrup, Denmark) according to the guidelines of the Dutch Society of Medical Microbiology [17].

Carbapenemases production was confirmed by carbapenemases double disk synergy test [18]. Enhancement of the inhibition zone in the area between the inhibitor-containing disk (boronic acid and/or dipicolinic acid) and any one of the two carbapenem discs used (meropenem and/or imipenem) was regarded as a positive result [17, 19].

Characterization of β-lactamase-encoding genes
ESBL phenotypes were analyzed for the presence of genes encoding blaTEM, blaSHV and blaCTX-M by real-time PCR using primers described before [20–22]. Carbapenem-resistant isolates were tested for the presence of genes encoding blakPC, blanDM, blaqXXA-48, blaimB and blavIM by multiplex PCRs as previously described [23]. DNA extraction was done by a boiling lysis method as described [24]. The PCR Amplification conditions were described elsewhere [25, 26].

DNA sequencing analysis
The Purified PCR products of ESBL producers were sequenced with the Sanger ABI 3730 XL automated DNA sequencer by a commercial company (BaseClear, Leiden, The Netherlands). Nucleotide sequences were aligned by the Codon Code Aligner software (Version 5.0.2) and compared to sequences available at the National Center for Biotechnology Information website (www.ncbi.nlm.nih.gov).

E. coli Phylogroups
E. coli isolates were segregated into phylogroups (A, B1, B2 or D) by a triplex PCR targeting chuA, yjaA and the TspE4.C2 DNA fragment, as developed by Clermont et al. [27].

Statistical analysis
All statistical analyses were performed according to Newcombe, Robert G [28].

| Species            | No. of isolates | No. of ESBL positive isolates (%) | CTX-M alone | CTX-M + TEM | CTX-M + SHV | TEM + SHV | CTX-M + TEM + SHV |
|--------------------|-----------------|----------------------------------|-------------|-------------|-------------|-----------|------------------|
| E. coli            | 72              | 51 (70.83)                       | 38          | 3           | 2           | 0         | 1                |
| Klebsiella pneumonia | 23              | 19 (82.61)                       | 0           | 0           | 10          | 1         | 8                |
| Enterobacter spp   | 3               | 2 (66.66)                        | 1           | 1           | 0           | 0         | 0                |
| Salmonella spp     | 1               | 1 (100)                          | 1           | 0           | 0           | 0         | 0                |
| Other species      | 14              | 0 (0)                            | 0           | 0           | 0           | 0         | 0                |
| Total              | 113             | 73 (64.61)                       | 40          | 4           | 12          | 1         | 9                |

Results
Sixty-eight out of 100 feces samples yielded ESBL-E while CPE was identified in 5% of these samples. Some samples demonstrated the growth of more than one species of Enterobacteriaceae, resulting in 113 isolates available for analysis. ESBLs were identified in 64.61% (73/113) (with 95% confidence interval (CI): 55.44–72.80) of the isolates and five (4.42%) (95% CI: 1.9–9.94) isolates showed carbapenemase activity. The prevalence of different ESBL types among the different Enterobacteriaceae species is shown in Table 1. It was highest in Klebsiella pneumoniae. Because only one Salmonella strain isolated, which produced CTX-M, we could not estimate the prevalence of ESBL-production in this species. All five carbapenem-resistant Enterobacteriaceae isolates were K. pneumoniae. CTX-M enzymes were detected in 89.04% (65/73) of the ESBL-producing Enterobacteriaceae, whereas SHV and TEM were detected in 30.14% (22/73) and 19.18% (14/73) respectively. The simultaneous presence of CTX-M, SHV, and TEM was identified in 9 isolates, 12 isolates coproduced CTX-M and SHV, 4 harbored CTX-M and TEM genes, one expressed SHV and TEM genes and 40 produced CTX-M genes only. Seven E. coli isolate expressed ESBL phenotype but no TEM, SHV or CTX-M were detected by PCR.

A summary of the distribution of different β-lactamase-encoding genes among different Enterobacteriaceae is shown in Table 1.

Three out of 5 carbapenem-resistant K. pneumoniae harbored blaNDM and 2 produced blavIM. No isolate expressed a combination of carbapenemase resistance genes. Of the 65 CTX-M – producing Enterobacteriaceae isolates, 52 (80%) produced CTX-M-15, five (7.7%) produced CTX-M-3, four (6.2%) produced CTX-M-14, one produced CTX-M-27, one produced CTX-M-32, and two, which belonged to CTX-M group 9, remained unidentified.

Antimicrobial susceptibility testing revealed that of the 73 ESBL-positive isolates, 58 (79.45%) expressed co-resistance to trimethoprim/sulfamethoxazole, 48 (65.75%) to quinolones (ciprofloxacin and/or norfloxacin), 33 (45.21%) to aminoglycosides (gentamicin and/or
tobramycin) and only one to nitrofurantoin. Twenty-two (30.14%) of the ESBL-positive isolates were multidrug resistant (MDR) (i.e. resistant to at least one agent in three or more classes of antimicrobials (aminoglycosides, quinolones and cotrimoxazole) [29]. The antimicrobial resistance pattern of CPE is provided in Table 2.

Phylogenetic analysis of E. coli isolate revealed that, ESBL-positive isolates were evenly distributed over the different phylogroups, while phylogroup A was underrepresented among ESBL-negative E. coli (Table 3).

Discussion
This study was conducted to determine the prevalence of extended-spectrum β-lactamase and carbapenemase production among Enterobacteriaceae isolates recovered from the feces of ambulatory patients with community-onset gastrointestinal complaints admitted to El-Ahrar General Hospital, Zagazig, Egypt.

Our findings showed that almost two in every three Egyptian patients with community-onset gastrointestinal complaints are carriers of ESBL-E. Furthermore, nearly 5% of these patients were colonized with CPE. This high rate of colonization with ESBL-E and CPE is most likely due to imprudent antimicrobial use, as in Egypt and other developing countries, antimicrobial agents are readily available and can be purchased as a commodity. What is more, many Egyptian patients receive antimicrobial treatment without the advice or prescription of a physician or other trained health care provider. Also, even when the antimicrobial treatment is officially prescribed, it is almost entirely empirical and not based on individual susceptibility data nor on surveillance data [30]. Overall, the rate of fecal ESBL-E demonstrated in our study is higher than reported from many other countries in Africa, Asia, Europe and North America, but lower than what has been described for Thailand [9–13, 31–34].

The prevalence of fecal ESBL-E found in a study conducted in Cairo by Abdul Rahman and El-Sherif in 2011, was similar to what we observed [14]. In that study, ESBL-E were detected phenotypically, without genotypic confirmation and the prevalence of CPE was not determined.

CTX-M enzymes were the most common β-lactamases among the Enterobacteriaceae isolates, followed by SHV and TEM. These results are consistent with those of previous studies from other countries around the world [11–13, 35, 36] that reported the dominance of CTX-M over other types of ESBLs. Which CTX-M alleles are dominant may differ by geographical region; we found that CTX-M-15 was the most frequently identified genotype among CTX-M–producing Enterobacteriaceae isolates. These findings confirm the reports of the worldwide spread and predominance of CTX-M-15 [37, 38].

Approximately one in every 20 patients included in our study, was colonized with CPE. This high frequency of carriage of CPE has not been described before in any African country and is quite alarming. It raises public health concern about the efficacy of carbapenems, which are the last resort for treatment of multidrug-resistant enterobacterial infections [39].

The blaNDM gene was identified in three of the five Klebsiella pneumoniae isolates which showed a carbapenem–resistant phenotype while the other two isolates expressed a blaVIM gene.

Our findings of NDM–producing isolates among patients who had no identified epidemiological link with the Indian subcontinent, the main reservoir of these isolates, along with the recent reports of NDM–producing Enterobacteriaceae derived from Egyptian septicemic patients and from retail chicken meat in Zagazig, Egypt [40, 41], support the hypothesis of the presence of autochthonous NDM–producing strains in the Middle East region [42].

The presence of Enterobacteriaceae producing NDM or VIM has been documented recently in several countries in the Middle East and North Africa [41, 43–45]. All reports, however, are case reports, describing the

---

**Table 2** The antimicrobial resistance pattern of CPE

| Sample No. | Gentamicin | Tobramycin | Ciprofloxacin | Norfloxacin | Nitrofurantoin | Cotrimoxazole |
|------------|------------|------------|---------------|-------------|----------------|---------------|
| 1          | R⁺         | R          | S             | S           | S              | R             |
| 2          | R          | R          | S             | S           | S              | R             |
| 3          | R          | R          | I             | R           | S              | R             |
| 4          | S⁻         | R          | R             | R           | R              | R             |
| 5          | R          | R          | R             | R           | S              | R             |

* R resistant, S sensitive

**Table 3** Phylogenetic groups of E-coli isolates

| Phylogroups | No. of ESBL positive E.coli | No. of ESBL-negative E.coli |
|-------------|-----------------------------|-----------------------------|
| A           | 11                          | 2                           |
| B1          | 10                          | 8                           |
| B2          | 17                          | 5                           |
| D           | 13                          | 6                           |
| Total       | 51                          | 21                          |
molecular characteristics of a few strains isolated from clinical specimens in hospitalized patients. Our study is the first that documents the prevalence, hence the size of the problem, in community-dwelling persons.

The antibiotic susceptibility testing revealed that four-fifths of ESBL-positive isolates were also resistant to trimethoprim/sulfamethoxazole, nearly two-thirds also to quinolones, and one-third also to aminoglycosides. Approximately half of the isolates were multidrug resistant, which stresses the public health threat by these isolates, which leave few options for treatment. Nitrofurantoin still had good activity against ESBL-E and CPE.

ESBL- E. coli isolates mainly belonged to the virulent groups B2/D, whereas ESBL- negative E. coli isolates were nearly equally distributed over the commensal groups A/ B1 and the virulent groups B2/D. This finding suggests that there may be a relationship between virulence and resistance determinants, in contrast to the previously suggested trade-off between virulence and resistance [46].

Conclusion
In conclusion, nearly two third of the Enterobacteriaceae isolates recovered from feces of Egyptian patients in Zagazig region with community-onset gastrointestinal complaints were ESBL producers and one in every 20 patients included in our study was colonized with CPE. These high rates call for better surveillance of resistance in Egypt, and for a more prudent antimicrobial use. Regulation of sales of antimicrobial agents, as recently introduced in India would be a large step forward [47].

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable

Ethics approval and consent to participate
This study was approved by the institutional Review Board of the Research Ethics Committee, Faculty of Medicine, Zagazig University. Informed written consent was obtained from all participants in this study.

Author details
1Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, The Netherlands. 2Laboratory for Medical Microbiology and Public Health, Hengelo, The Netherlands. 3Department of Microbiology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt. 4National Laboratory for Veterinary Quality Control on Poultry Production, Animal Health Research Institute, Dokki, Giza, Egypt. 5Department of Virology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.

Received: 4 January 2017 Accepted: 5 June 2017
Published online: 13 June 2017

References
1. Shaikh S, Fatima J, Shalik S, Rizvi SMD, Kamal MA. Antibiotic resistance and extended-spectrum beta-lactamases: types, epidemiology and treatment. Saudi J Biol Sci. 2015;22:96–101. [cited 2016 Mar 31]. Available from: http://www/pubmedcentral.nih.gov/articlerender.fcgi?artid=4281622&tool=pmcentrez&rendertype=abstract
2. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:933–51. [cited 2014 Dec 27]. table of contents. Available from: http://cmr.asm.org/content/14/4/933.abstract?ijkey= e4ed374e9991270b273b3ab1470247e4f10514325&keytype2=tf_ipsecsha
3. de Kraker MEA, Jarlier V, Momen JCM, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteremia in Europe: trends from the European antimicrobial resistance surveillance system. Clin Microbiol Infect. 2013;19:860–8. [cited 2015 Jan 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23039210
4. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteraemia with extended-spectrum-beta-lactamase-producing bacteriae. Antimicrob Agents Chemother. 2006;50:1257–62. [cited 2015 Feb 11]. Available from: http://aac.asm.org/content/50/4/1257.abstract?ijkey= 89ea062a2b38fe136a3b3aaee27dbd752510514325&keytype2=tf_ipsecsha
5. Lukac PJ, Bonomo RA, Logan LK. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: Old foe, Emerging Threat. Clin. Infect. Dis. 2015; [cited 2015 Feb 5] ccid:020. Available from: http://cid.oxfordjournals.org/content/early/2015/01/15/ccid:020.short
6. Girlich D, Bouhlat N, Poirel L, Benouda A, Nordmann P. High rate of faecal carriage of extended-spectrum beta-lactamase and OXA-48 carbapenemase-producing Enterobacteriaceae in a university hospital in Morocco. Clin Microbiol Infect. 2014;40:350–4. [cited 2015 Feb 10]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23927757
7. Mirelis B, Navarro F, Miró E, Mesa RJ, Coll P, Prats G. Community transmission of extended-spectrum beta-lactamase. Emerg Infect Dis. 2003;9:1024–5. [cited 2015 Mar 2]. Available from: http://www.ncbi.nlm.nih.gov/gov/articlerender.fcgi?artid=3020612&tool=pmcentrez&rendertype=abstract
8. Luvsanhariah UJ, Hirai I, Nakata A, Ikuma K, Yamauchi K, Niki M, et al. Prevalence of and risk factors associated with faecal carriage of CTX-M beta-lactamase-producing Enterobacteriaceae in rural Thai communities. J Antimicrob Chemother. 2012;67:1769–74. [cited 2014 Mar 25]. Available from: http://j-ac.oxfordjournals.org/content/67/7/1769.abstract?ijkey= 4534e73fe11b565dc74a110ae6de8e071f3ba83&keytype2=tf_ipsecsha
9. Li B, Sun J-Y, Liu Q-Z, Han L-Z, Huang X-H, Ni Y-X: High prevalence of CTX-M beta-lactamases in faecal Escherichia coli strains from healthy humans in Fuzhou, China. Scand J Infect Dis. 2011;43:170–4. [cited 2015 Mar 23]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21128708
10. Valverde A, Coque TM, Sánchez-Moreno MP, Rollán A, Baquero F, Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum
beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol. 2004;42:769–75. [cited 2015 Mar 2]. Available from: http://www.pubmedcentral.nih.gov/articleinfo.fcgi?artid=1797662&tool=pmcentre2&rendertype=abstract

26. Wang L, Gu H, Lu X. A rapid low-cost real-time PCR for the detection of Klebsiella pneumoniae carbapenemase genes. Ann Clin Microbiol Antimicrob. 2012;11:9. [cited 2014 Nov 28]. Available from: http://www.pubmedcentral.nih.gov/articleinfo.fcgi?artid=3375436&tool=pmcentre2&rendertype=abstract

27. Clermont O, Boncorsi S, Bingen E. Rapid and simple determination of the Escherichia Coli phylogenetic group. Appl Environ Microbiol. 2000;66:4555–8. [cited 2014 Nov 27] Available from: http://www.pubmedcentral.nih.gov/articleinfo.fcgi?artid=9234240&tool=pmcentre2&rendertype=abstract

28. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857–72. [cited 2016 May 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9595616

29. Epstein S. Small Animal Critical Care Medicine. Small Anim. Crit. Care Med. Elsevier, 2015 [cited 2014 Oct 13]. Available from: http://www.sciencedirect.com/science/article/pii/B978014503067001033

30. Knobler SL, Lemon SM, Najafi M, Burroughs T. Factors Contributing to the Emergence of Resistance [Internet]. National Academies Press (US); 2003 [cited 2015 Mar 23]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK97126/

31. Ahmed SF, MAM A, Mohamed ZK, Moussa TA, Klena JD. Fecal carriage of extended-spectrum β-lactamases and AmpC-producing Escherichia Coli in a Libyan community. Ann Clin Microbiol Antimicrob. 2014;13:22. [cited 2015 Feb 9]. Available from: http://www.ann-clinmicrob.com/article/content/13/1/22

32. Ben Sallem R, Ben Slama K, Estepa V, Jouini A, Ghara A, Klibi N, et al. Prevalence and characterisation of extended-spectrum beta-lactamase (ESBL)-producing Escherichia Coli isolates in healthy volunteers in Tunisia. Eur J Clin Microbiol Infect Dis. 2012;31:1511–6. [cited 2015 Feb 20]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22065280

33. Luvsansharav U-O, Hirai I, Niki M, Nakata A, Yoshinaga A, Moriyama T, et al. Prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae among healthy adult people in Japan. J Infect Chemother. 2011;17:722–5. [cited 2015 Apr 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21359543

34. Kader AA, Kumar A, Kamath KA. Fecal carriage of extended-spectrum β-lactamase-producing Escherichia Coli and Klebsiella Pneumoniae in patients and asymptomatic healthy individuals. Infect Control Hosp Epidemiol. 2007;28:1114–6. [cited 2015 Mar 23]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17932839

35. Zhang J, Zheng B, Zhao L, Wei Z, Ji J, Li L, et al. Nationwide high prevalence of CTX-M and an increase of CTX-M-55 in Escherichia Coli isolated from patients with community-onset infections in Chinese county hospitals. BMC Infect Dis. 2014;14:659. [cited 2015 Apr 9]. Available from: http://www.biomedcentral.com/1471-2334/14/659

36. Pournaras S, Ikonomidis A, Kristo I, Tsakris A, Maniatis AN. CTX-M enzymes are the most common extended-spectrum beta-lactamases among Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:5437–45. [cited 2015 Apr 9]. Available from: http://jac.oxfordjournals.org/content/54/2/574.full

37. Rosolini GM, D’Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum beta-lactamase-producing Escherichia Coli. J Clin Microbiol. 2008;46:S133–41. [cited 2014 Jun 10]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18154526

38. Cantón R, Coque TM. The CTX-M beta-lactamae pandemic. Curr Opin Microbiol. 2006;9:466–75. [cited 2015 Apr 10]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16942999

39. Vardakas KZ, Tansarli GS, Raffalidis PJ, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteremia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:2793–803. [cited 2015 Apr 9]. Available from: http://jac.oxfordjournals.org/content/67/12/2793.abstract?ijkey= g05e6b25a38e8a0e8b073d13659c090e&keytype2=tf_journal

40. Abdallah HM, Reuland EA, Wintersma BB, Al Naiemi N, Koek A, Abdelwahab AM, et al. Extended-Spectrum β-Lactamases and/or Carbapenemases-Producing Enterobacteriaceae Isolated from Retinal Chicken Meat in Zagazig, Egypt. PLoS One. Public Library of Science; 2015 [cited 2015 Nov 12]10:e0136652. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103171/
41. Abdallah HM, Wintermans BB, Reuland EA, Koek A, al Naiemi N, Ammar AM, et al. Extended-Spectrum β-Lactamase- and Carbapenemase-Producing Enterobacteriaceae Isolated from Egyptian Patients with Suspected Blood Stream Infection. PLoS One [Internet]. Public Library of Science; 2015 [cited 2015 Nov 12];10:e0128120. Available from: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0128120

42. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends Microbiol. [Internet]. 2011;19:588–595 [cited 2015 Mar 24]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22078325.

43. Sonnevend A, Al Baloushi A, Ghazawi A, Hashmey R, Girgis S, Hamadeh MB, et al. Emergence and spread of NDM-1 producer Enterobacteriaceae with contribution of IncX3 plasmids in the United Arab Emirates. J Med Microbiol. 2013;62:1044–50. [cited 2014 Oct 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23579399

44. Shahcheraghi F, Nobari S, Rahmati Ghezelgeh F, Nasiri S, Owlia P, Nikbin VS, et al. First report of New Delhi metallo-beta-lactamase-1-producing Klebsiella Pneumoniae in Iran. Microb Drug Resist. 2013;19:30–6. [cited 2014 Oct 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22994942

45. Nordmann P, Nasir T, Poirel L, Carbapenemases CA. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17:1791–8.

46. Clermont O, Lavallay M, Vimont S, Deschamps C, Forestier C, Branger C, et al. The CTX-M-15-producing Escherichia Coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother. 2008;61:1024–8. [cited 2015 Apr 13]. Available from: http://jac.oxfordjournals.org/content/61/5/1024.abstract?ijkey=bb2871207050a89bd7b8255b3666af11a677e&keytype2=tf_ipsecsha

47. Ghafur A. Perseverance, persistence, and the Chennai declaration. Lancet. Infect. Dis. [Internet]. Elsevier; 2013 [cited 2015 Nov 17];13:1007–8. Available from: http://www.thelancet.com/article/S1473309913703141/fulltext

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit